Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.
The RNA interference therapeutic targeting synthesis of angiotensinogen lowered BP in adults with mild to moderate hypertension for up to 6 months after one dose in the phase 2 KARDIA-1 study.
New research found that improving diet quality did not protect against breast cancer recurrence overall; however, a subset of women who made the greatest dietary changes did benefit.
In a new data analysis, Harvard researchers find that insulin manufacturers have filed multiple patents on delivery devices following the original insulin product approval.